With proper planning, realistic expectations, and qualified surgical care, patients can successfully complete their transformation and enjoy the full benefits of their weight loss achievement.
PEX-168 is a China-domestic long-acting GLP-1R agonist approved by the China's FDA for marketing and used for blood glucose control of adult patients with T2DM
This helps lower both fasting and after-meal glucose levels in a more physiologic way
These methods were also used extensively to estimate the size of various subsegments in the market
The potential success of this approach is enhanced given that GIP, GLP-1, and GLP-2 based drugs are already in clinical use, although postulated benefits on bone health still need to be fully confirmed ( Figure 3 )
Their cardiovascular value evident in clinical trials has also expanded their usage in cardiovascular morbidity